AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,705.50GBp
11:36am EDT
Change (% chg)

-44.00p (-0.93%)
Prev Close
4,749.50p
Open
4,750.00p
Day's High
4,761.00p
Day's Low
4,673.50p
Volume
2,452,921
Avg. Vol
2,673,336
52-wk High
4,946.41p
52-wk Low
4,075.00p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC is the United Kingdom-based global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes... (more)

Overall

Beta: 0.37
Market Cap(Mil.): £60,010.01
Shares Outstanding(Mil.): 1,263.50
Dividend: 125.00
Yield (%): 3.75

Financials

  AZN.L Industry Sector
P/E (TTM): 73.29 41.06 41.71
EPS (TTM): 0.65 -- --
ROI: 3.05 16.86 16.20
ROE: 5.75 17.36 17.00
Search Stocks

Astrazeneca drug deal hoists Innate Pharma shares to record high

PARIS - Shares in Innate Pharma surged to a record high on Friday as investors cheered a deal with AstraZeneca to accelerate and broaden development of its immune-boosting anti-cancer medicines that could earn the French firm $1.275 billion.

24 Apr 2015

AstraZeneca insists Celgene deal about strategy, not cash

LONDON - AstraZeneca is getting a $450 million windfall by letting Celgene develop a prized immunotherapy drug for blood cancers but its chief executive insists the deal is about strategy, not cash.

24 Apr 2015

CORRECTED-AstraZeneca insists Celgene deal about strategy, not cash

LONDON, April 24 - AstraZeneca is getting a $450 million windfall by letting Celgene develop a prized immunotherapy drug for blood cancers but its chief executive insists the deal is about strategy, not cash.

24 Apr 2015

BRIEF-AstraZeneca open to acquisitions, smaller deals more likely

* CEO says no comment on Pfizer, completely focused on developing pipeline

24 Apr 2015

AstraZeneca looks beyond Nexium hit with new cancer deals

LONDON - AstraZeneca has sharpened its focus on cancer drugs with two new deals as it looks beyond a hit to sales and profits from the launch of cheap copies of its popular stomach acid pill Nexium in the vital U.S. market.

24 Apr 2015

UPDATE 2-AstraZeneca looks beyond Nexium hit with new cancer deals

* Drugmaker reiterates financial forecasts for year (Adds analyst comment, latest shares)

24 Apr 2015

AstraZeneca hit by copycat Nexium and strong dollar in Q1

LONDON, April 24 - AstraZeneca's sales fell by a slightly less-than-expected 6 percent in the first quarter, hit by the launch of generic copies of its popular stomach acid pill Nexium in the vital U.S. market and the strong dollar.

24 Apr 2015

BRIEF-AstraZeneca holds 2015 guidance after Q1 core EPS of $1.08

* Fy 2015 guidance is unchanged from that provided on 6 march 2015

24 Apr 2015

BRIEF-Innate Pharma and AstraZeneca announce immuno-oncology agreement

* Announces global agreement with AstraZeneca for IPH2201 in immuno-oncology

24 Apr 2015

AstraZeneca, Juno latest to collaborate on immuno-oncology drugs

- A unit of AstraZeneca Plc has teamed up with Juno Therapeutics Inc to develop combination treatments that use the body's immune system to kill cancer cells.

23 Apr 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$49.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks